Zydus receives Final Approval from the USFDA for Levothyroxine Sodium for Injection

Ahmedabad, India, 28 March, 2023

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereinafter referred to as "Zydus") has received final approval for Levothyroxine Sodium for Injection, 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial from the United States Food and Drug Administration (USFDA).

Levothyroxine Sodium Injection is indicated for the treatment of myxedema coma. The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara (India).

The group now has 354 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.

(*as of 31st December 2022)

***

PRESS RELEASE

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)
Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878